cancer patients dates back to 1975 [1], its use has never gained wide acceptance among oncologists. Only in recent years has HPN prompted renewed interest [2-4], possibly because the availability of new anticancer drugs made imperative allowing completion of scheduled therapies to achieve full benefit despite treatment-associated toxicities. A major barrier to development and implementation of HPN programmes in cancer patients is the lack of statistically robust randomized controlled trials (RCTs), which inform strong recommendations in international guidelines. However, it has been already noted [5] that the peculiar design of nutrition trials may not fully fit the procedures required to issue guidelines. In particular, the inclusion of a no-nutrition arm may not be ethically possible when hypo- or aphagic cancer patients are studied. Furthermore, the growing awareness of the role of inflammation in the pathophysiology of cancer cachexia has led some oncologists to underestimate the potential of nutritional support as if the hypophagic cachectic patient ceased to require nutritive substrates to sustain the body's physiologic functions. Finally, the uncertainty about the indications of HPN is also due

SINPE Position Paper on the use of home parenteral nutrition in cancer patients

Zanetti, Michela
2022-01-01

Abstract

cancer patients dates back to 1975 [1], its use has never gained wide acceptance among oncologists. Only in recent years has HPN prompted renewed interest [2-4], possibly because the availability of new anticancer drugs made imperative allowing completion of scheduled therapies to achieve full benefit despite treatment-associated toxicities. A major barrier to development and implementation of HPN programmes in cancer patients is the lack of statistically robust randomized controlled trials (RCTs), which inform strong recommendations in international guidelines. However, it has been already noted [5] that the peculiar design of nutrition trials may not fully fit the procedures required to issue guidelines. In particular, the inclusion of a no-nutrition arm may not be ethically possible when hypo- or aphagic cancer patients are studied. Furthermore, the growing awareness of the role of inflammation in the pathophysiology of cancer cachexia has led some oncologists to underestimate the potential of nutritional support as if the hypophagic cachectic patient ceased to require nutritive substrates to sustain the body's physiologic functions. Finally, the uncertainty about the indications of HPN is also due
2022
Pubblicato
https://www.sciencedirect.com/science/article/pii/S0899900721004408?via=ihub
File in questo prodotto:
File Dimensione Formato  
2022 Bozzetti.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 524.22 kB
Formato Adobe PDF
524.22 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
2022+Bozzetti-Post_print.pdf

Open Access dal 11/01/2023

Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Creative commons
Dimensione 970.52 kB
Formato Adobe PDF
970.52 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3052970
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact